Methods for compact cyclotron production of indium-111 for medical use

MacDonald, Norman S.; Neely, H. H.; Wood, Richard; Takahashi, Jun-ichi; Wakakuwa, S.I.; Birdsall, R. L.

doi:10.1016/0020-708x(75)90084-8

Cited by 21 publications

(9 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The production of 111 In is well-established and can be achieved directly via nat Cd(d,xn), nat Cd(p,xn), nat Cd(α,x), nat Ag(α,xn), nat Ag( 7 Li,x), or nat Ag( 11 B,x) or indirectly by nat Rh( 12 C, x) 111 Sb → 111 Sn → 111 In, nat Sn(n,x) 111 Sn → 111 In, or nat Sn(p,x) 111 Sn → 111 In. − The most common production methods are proton or deuteron bombardment of natural or enriched cadmium targets or α bombardment of silver targets. These methods are popular because they can achieve high yields of nca 111 In while avoiding or minimizing the production of the long-lived contaminant 114m In ( t 1/2 = 1188 h).…”

Section: Indiummentioning

confidence: 99%

Radioactive Main Group and Rare Earth Metals for Imaging and Therapy

2018

View full text Add to dashboard Cite

Radiometals possess an exceptional breadth of decay properties and have been applied to medicine with great success for several decades. The majority of current clinical use involves diagnostic procedures, which use either positron-emission tomography (PET) or single-photon imaging to detect anatomic abnormalities that are difficult to visualize using conventional imaging techniques (e.g., MRI and X-ray). The potential of therapeutic radiometals has more recently been realized and relies on ionizing radiation to induce irreversible DNA damage, resulting in cell death. In both cases, radiopharmaceutical development has been largely geared toward the field of oncology; thus, selective tumor targeting is often essential for efficacious drug use. To this end, the rational design of fourcomponent radiopharmaceuticals has become popularized. This Review introduces fundamental concepts of drug design and applications, with particular emphasis on bifunctional chelators (BFCs), which ensure secure consolidation of the radiometal and targeting vector and are integral for optimal drug performance. Also presented are detailed accounts of production, chelation chemistry, and biological use of selected main group and rare earth radiometals.

show abstract

Section: Indiummentioning

confidence: 99%

Radioactive Main Group and Rare Earth Metals for Imaging and Therapy

2018

View full text Add to dashboard Cite

show abstract

“…Indium-111 is produced commercially by irradiating a natural cadmium target with high-energy protons in a cyclotron according to the 111 Cd(p,n) 111 In or 112 Cd(p,2n) 111 In reaction, and both remain the most widely used 111 In production methods. [31][32][33] When production of 111 In is carried out by bombarding the Cd target with protons, the 111 In activity at the end of bombardment (EOB) contains radionuclidic contaminations, such as 109 In (t ½ = 4.3 hours), 110m In (t ½ = 4.9 hours), and 114m In (t ½ = 49 days). The first two radionuclides of indium have a relatively short half-life and hence cooling for 24 hours after EOB will reduce their contaminations.…”

Section: Production Of Radionuclides Currently Used In Prrtmentioning

confidence: 99%

“…Liquidliquid extraction and ion-exchange chromatography (IEC) are widely used for radiochemical separation of 111 In on the commercial scale. 31,32,[35][36][37][38][39] However, despite the development of robust separation and purification technology, low production yields are a major impediment in the large-scale production of 111 In required for its therapeutic use.…”

Section: Production Of Radionuclides Currently Used In Prrtmentioning

confidence: 99%

Peptide Receptor Radionuclide Therapy: An Overview

Dash

Chakraborty

Pillai³

et al. 2015

Cancer Biotherapy and Radiopharmaceuticals

100

101

View full text Add to dashboard Cite

Peptide receptor radionuclide therapy (PRRT) is a site-directed targeted therapeutic strategy that specifically uses radiolabeled peptides as biological targeting vectors designed to deliver cytotoxic levels of radiation dose to cancer cells, which overexpress specific receptors. Interest in PRRT has steadily grown because of the advantages of targeting cellular receptors in vivo with high sensitivity as well as specificity and treatment at the molecular level. Recent advances in molecular biology have not only stimulated advances in PRRT in a sustainable manner but have also pushed the field significantly forward to several unexplored possibilities. Recent decades have witnessed unprecedented endeavors for developing radiolabeled receptor-binding somatostatin analogs for the treatment of neuroendocrine tumors, which have played an important role in the evolution of PRRT and paved the way for the development of other receptor-targeting peptides. Several peptides targeting a variety of receptors have been identified, demonstrating their potential to catalyze breakthroughs in PRRT. In this review, the authors discuss several of these peptides and their analogs with regard to their applications and potential in radionuclide therapy. The advancement in the availability of combinatorial peptide libraries for peptide designing and screening provides the capability of regulating immunogenicity and chemical manipulability. Moreover, the availability of a wide range of bifunctional chelating agents opens up the scope of convenient radiolabeling. For these reasons, it would be possible to envision a future where the scope of PRRT can be tailored for patient-specific application. While PRRT lies at the interface between many disciplines, this technology is inextricably linked to the availability of the therapeutic radionuclides of required quality and activity levels and hence their production is also reviewed.

show abstract

“…However, the etched solution might contain, in addition to the target matrix, the supporting material (in varying quantities), which is copper in many situations, and the radiochemical separation procedures should be capable of tackling this situation. Separation of rain from cadmium has been reported previously (Dahl and Tilbury, 1972 [3]; MacDonald et al, 1975 [10]; Zaitseva et al, 1990 [15]). Separation of 111 ln from an active etched solution containing cadmium, iron and aluminum impurities has also been reported (Brown, L. C. et.…”

Section: Introductionmentioning

confidence: 67%

A New Cost Technique for Separation of Indium-111 Isotope Produced From Cadmium Target in Low Energy Cyclotron .

Hanafi¹

2008

The International Conference on Chemical and Environmental Engi

View full text Add to dashboard Cite

A radiochemical procedure for the separation of carrier-free 111 In from cadmium target is described. 111 In is produced produced by the bombardment of a natural Cd-111 target by proton particles. The separation is carried out by the difference in the sorption of indium, cadmium and copper on an activated carbon samples. Laboratory studies were conducted to evaluate and optimize the various process variables (shaking time, pH and effect of buffer). A quantitative determination of the adsorptive capacity of activated carbons to separated these metals was also determined. The distribution coefficients of the three elements onto different types of adsorbents were evaluated in 0.05M HCl and 1M acetate buffer at pH 4 to find the best conditions for separation of 111 In isotope from Cd and Cu.

show abstract

Methods for compact cyclotron production of indium-111 for medical use

Cited by 21 publications

References 10 publications

Radioactive Main Group and Rare Earth Metals for Imaging and Therapy

Radioactive Main Group and Rare Earth Metals for Imaging and Therapy

Peptide Receptor Radionuclide Therapy: An Overview

A New Cost Technique for Separation of Indium-111 Isotope Produced From Cadmium Target in Low Energy Cyclotron .

Contact Info

Product

Resources

About